USC ALS Center of Excellence Clinical Trials

#Disease CategoryTitleClinicalTrials.gov StatusClinicalTrials.gov Link
1ALSHealey Platform Trial: Regimen I NUZ-001
NUZ-001, also known as (S)-monepantel, is a synthetic drug with a formula of C20H13F6N3O2S. NUZ-001 has been shown to enhance autophagy by suppression of the mTOR signaling pathway and can significantly reduce TDP-43 aggregation addressing the core pathology of ALS.		RecruitingClick here
2ALSPerpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen G: DNL343)CompletedClick here
3ALSPerpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen F: ABBV-CLS-7262)CompletedClick here
4ALSA phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)Recruitment is completed; study is ongoingClick here
5ALSA prospective, multicenter, randomized, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)Study is on hold Click here
6ALSA Two-part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open Label Extension, Multicenter Study of the Efficacy and Safety of NurOwn in Participants with Amyotrophic Lateral SclerosisStudy is on hold 
7ALSOxidative Markers and Efficacy in ALS /MND Phenotypes treated with EdaravoneRecruitingClick here
8ALSA randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open label extension phase(Novartis CLOU0644O12301) RecruitingClick here
9Myasthenia GravisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia GravisRecruitingClick here
10Myasthenia Gravis         IMVT1402-3101-MYASTHENIARecruitingClick here
11Myasthenia GravisA Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathy(MOBILIZE study)RecruitingClick here
12CIDPA Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (VITALIZE study)RecruitingClick here
13CIDPAn Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body MyositisActive, not recruitingClick here